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Background: Bactericidal-permeability-increasing protein (BPI) is a potent anti-microbial protein produced by neutrophil granulocytes.
Anti-neutrophil cytoplasmatic antibodies (ANCA) directed against BPI have been detected in up to 91% in patients with cystic fibrosis (CF).
We aimed to evaluate the prevalence of BPI-ANCA in our CF patients and to determine whether presence of BPI-ANCA is correlated with
organ damage. Methods: Twenty-four patients performed respiratory function testing and pulmonary high-resolution computed tomography
(HRCT). HRCT was scored by using a modified Bhalla method. Serum samples were analysed by direct binding enzyme-linked
immunosorbent assay for BPI-ANCA. Results: The prevalence of anti-BPI-IgG was 71% and anti-BPI-IgA 33%. Twenty-nine percent of our
patients were positive for both BPI-ANCA isotypes. Mean HRCT score was 8.0 ranging from 0 to 22, bronchiectasis presented the most
common finding (79%). There was a significant correlation between BPI-ANCA and both HRCT score and FEV1 ( p < 0.01). High levels of
BPI-ANCA were correlated to chronic Pseudomonas aeruginosa lung infection ( p < 0.01). Conclusions: BPI-ANCA was common in our
study group. Highly significant correlations between BPI-ANCA and parameters to evaluate lung disease in CF may be a consequence of the
inflammation process, or it may indicate a pathogenic role of BPI-ANCA levels in the development of lung disease. More research is needed
and the clinical significance of our findings needs further evaluation.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Autoantibodies; X-ray tomography; Spirometry; Disease progression
1. Introduction effect. The C-terminal domain is important for the opsoni-Bactericidal-permeability-increasing protein (BPI) is a
55-kDa membrane associated protein found in the azuro-
philic granules of neutrophil granulocytes. BPI is the most
potent anti-microbial-granule protein identified so far and it
consists of two similar domains. The N-terminal domain
binds to lipopolysaccarides in the membrane of gram-
negative bacteria, for example Pseudomonas aeruginosa
(PSA), and has both endotoxin neutralising and bactericidal1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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Anti-neutrophil cytoplasmatic antibodies (ANCA) are
autoantibodies directed against different proteins in the
cytoplasm of neutrophil granulocytes, and they have been
used in diagnostic work-up as serological markers of
vasculitides since 1982 [2,3]. Recently, BPI has been
found to represent a major ANCA target antigen as well
[4]. Moreover, BPI-ANCA are detected in up to 91% in
patients with CF and they are claimed to worsen lung
inflammation and pulmonary function [5,6]. Because
more than 90% of all deaths are related to pulmonary
disease in cystic fibrosis (CF), early detection and longi-
tudinal assessment of lung parenchyma damage is a major
issue in managing CF. Pulmonary high-resolution com-
puted tomography (HRCT) has recently been considered
as the most promising imaging technique to assessed by Elsevier B.V. All rights reserved.
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[7–9].
The aim of this study has been to evaluate the prevalence
of BPI-ANCA in our study group and whether presence of
BPI-ANCA is correlated with organ damage in patients with
cystic fibrosis. We have therefore correlated BPI-ANCA
(isotype IgG and IgA) values to a common HRCT score for
cystic fibrosis [10] and to pulmonary function measured as
forced expiratory volume in one second (FEV1).2. Materials and methods
Haukeland University Hospital serves as a regional
centre for patients with CF in Western Norway. All 29 CF
patients more than 6 years of age were invited to take part
in the study, one adult patient refused, two sets of HRCT
scans and two sets of blood samples were lost leaving 24
patients enrolled in the study (13 female, 11 male). The
median age was 13 years (mean 16.6 years, S.D. 9.1, range
6–40 years).
The CF diagnosis was made by demonstration of repeated
elevated sweat chloride concentrations (mean 99.5 mmol/l,
S.D. 26.1) and typical clinical manifestations in all patients.
The mean forced vital capacity was 92.7% of predicted
(S.D. 19.3); the mean forced expiratory volume in one
second was 79.3% of predicted (S.D. 23.4). Eight patients
were found to be homozygous for the dF508 mutation
(33%); the remaining 16 patients either had two other
mutations (4 patients), 1 detectable mutation (5 patients)
or no detectable mutation (7 patients). We consider our CF
patient cohort to be representative of the Norwegian CF
population.
All patients had received conventional therapy for CF
for at least 6 months and they were in clinically stable
condition.
Data were collected between February 1999 and August
2000. Informed consent was obtained from patients and/or
their families. The regional ethics committee approved our
study protocol.
Our patients attend the outpatient department every
second–third month, or more often when needed. Chronic
lung infection with PSA was defined as two or more
precipitins or antibodies against P. aeruginosa (ELISA)
and repetitive sputum cultures of PSA within 6 months
[11]. Eight patients (33%) had chronic lung infection with
PSA and they have been given 12-day courses of intrave-
nous antibiotic treatment every third month.
Sixteen patients (67%) have been taking pancreatic
enzyme supplementation and the amount of lipase was
between 5000 and 10,000 IE/kg bodyweight/day.
Serum samples of all patients were analysed by direct
binding enzyme-linked immunosorbent assay (ELISA) for
BPI-ANCA isotypes IgG and IgA. The analysis was per-
formed at Wieslab AB, Lund (Sweden) as previously
described [12]. In short, antigens were coated in microtiterplates at a concentration of 1 Ag/ml in a carbonate buffer.
All samples were diluted 1/80 and incubated for 1 h. Bound
antibodies were detected using alkaline phosphatase-conju-
gated goat anti-human IgG (Sigma, Stockholm, Sweden)
and IgA (Eurodiagnostica, Malmo¨, Sweden). Anti-BPI-IgG
was quantified from a calibrator curve of serum that was
serially diluted and results expressed in arbitrary units (U).
For anti-BPI-IgA the results were expressed as optical
density (OD). In each ELISA analysis, one positive and
one negative control was analysed. Anti-BPI-IgG and anti-
BPI-IgA cut off was calculated from the results of 42 normal
sera + 3 S.D. Cut-off values were defined at 0.14 OD for IgA
and 27 U/ml for IgG.
Pulmonary HRCT (General Electrics, HiSpeed CT) was
performed using 1-mm thin sections and 10-mm intervals
during inspiration, followed by 1-mm thin sections with
20-mm intervals during expiration. A paediatric radiologist
evaluated the HRCT images and classified the findings
according to a modified scoring system as described by
Bhalla et al. [10]. The morphological criteria were based on
description of localisation and degree of pathological
changes. According to Bhalla, we evaluated bronchiectasis,
peribronchial thickening, mucus plugging, sacculations,
bullae, emphysema and collapse or consolidation. The
scoring system was extended in terms of mosaic perfusion
according to Helbich and colleagues. The obtainable score
ranged from 0 to maximal 27 points, the latter represented
extensive parenchymal damage. Standard spirometry was
assessed by Sensor Medics Vmax equipment (CA, USA).
FEV1 was chosen as a representative variable and it was
expressed as percent of predicted according to European
Coal and Steel reference set [13].
Data analysis was performed using a commercially
available software package (SPSS). Descriptive statistics
included mean, minimum and maximum values, standard
deviations and median. The relationship between BPI-
ANCA values and HRCT score and forced expiratory
volume in one second, respectively, was assessed by partial
correlations, adjusting for age, gender and chronic PSA lung
infection. The correlation between BPI-ANCA and PSAwas
evaluated by Kendall’s tau-b. All reported p-values are two-
tailed, p < 0.05 was considered significant and p < 0.01 was
considered highly significant.3. Results
Prevalence of anti-BPI-IgG in our study group was 71%
(17 out of 24 patients) with a mean value of 72.4 U/ml
(range 4–320 U/ml) and median of 36 U/ml. Anti-BPI
antibodies of IgA isotype were positive in 33% (8 out of
24 patients) with a mean of 0.26 OD (range 0–1.28 OD)
and median of 0.06 OD. Seven patients (29%) were positive
for both BPI-ANCA isotypes (Table 1).
The mean HRCT score in our CF group was 8F 6.6
(S.D.) ranging from 0 to 22 (median 6.5). Bronchiectasis
Table 1
Individual patient data, mean values and standard deviation of 24 patients with cystic fibrosis listed as age, BPI-ANCA values, HRCT score, FEV1 (%













6 0.02 74 5 99 9.3  Yes
7 0.02 55 0 91 15.8  Yes
8 0.02 26 1 85 8.8  Yes
8 0.03 62 7 78 8.2  No
8 0.36 41 10 73 14.6 + Yes
9 0.07 46 8 82 11.2  Yes
10 0.03 17 3 95 10.3  Yes
12 0.05 39 7 71 10.4  No
12 0.72 320 15 55 18.1 + Yes
12 0.74 56 15 65 15.8 + Yes
13 0 4 1 98 6.5  d Yes
13 0.01 27 5 101 15  No
13 0.01 17 1 112 15.3  Yes
13 0.04 32 3 99 10.7  No
17 0.29 29 9 69 16 + Yes
17 1.24 320 22 25 18.9 + Yes
21 0.08 33 3 91 12.7  Yes
22 0.09 13 4 84 8.1  No
23 1.28 320 15 37 21.2 + Yes
24 0.01 30 1 114 10.1  No
26 0.31 94 13 76 17.2 + Yes
30 0.01 2 6 102 11.1  No
34 0.13 74 19 61 15.4 + Yes
40 0.70 6 19 40 17.3  No
Mean = 16.6 0.26 72.4 8 79.3 13.3
S.D. = 9.1 0.39 98.4 6.6 23.4 4.0
a Cut-off values were defined as 0.14 (OD) for IgA and 27 (U/ml) for IgG.
b PSA= chronic PSA lung infection.
c Faecal elastase-1 < 200 Ag/g faeces.
d Intermittently PSA lung infection.
Fig. 1. Correlation between anti-BPI-IgA (OD) and HRCT score in 24
patients with cystic fibrosis (r = 0.67, p< 0.01); the graph reflects a
regression line.
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Bronchiectases were graded as mild in 10, moderate in 6
and severe in 3 of these 19 patients. Peribronchial
thickening was the second most common finding and
was found in 17 patients (71%); all of them were graded
as mild. Mucus plugging was present in 15 patients
(63%), 8 patients had mucus plugging in 1–5 broncho-
pulmonary segments, 2 patients had mucus plugging in
6–9 segments and 5 patients in more than nine segments.
Moreover, we detected consolidations in 12 patients,
sacculations in 7 patients, mosaic perfusion in 8 patients
and bullae in 4 patients. One patient had emphysema,
none had abscesses.
Individual results of age, BPI-ANCA values, HRCT
score, FEV1 (% predicted), serum immunoglobulin G levels,
chronic PSA lung infection and maldigestion are presented
in Table 1.
There was a significant correlation between BPI-ANCA
values and HRCT score (r= 0.67, p < 0.01 for IgA; r= 0.48,
p = 0.029 for IgG). High titers of BPI-ANCA were correlat-
ed with a high HRCT score. Fig. 1 shows the correlation
between anti-BPI-IgA and HRCT score.
Furthermore, there was a significant correlation between
BPI-ANCA and FEV1 (% predicted, r = 0.75, p < 0.01 forIgA; r = 0.54, p = 0.012 for IgG). High titers of BPI-ANCA
were correlated with impaired pulmonary function as mea-
sured by FEV1 (Fig. 2).
Fig. 2. Correlation between anti-BPI-IgA (OD) and FEV1 (% predicted) in
24 patients with cystic fibrosis (r = 0.75, p< 0.01); the graph reflects a
regression line.
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chronic PSA lung infection (r = 0.650, p < 0.01 for IgA;
r = 0.532, p < 0.01 for IgG) as shown in Table 1.4. Discussion
ANCA have been used as serological markers in routine
diagnostic work-up of patients with autoimmune disorders
like Wegener’s granulomatosis or microscopic polyangitis
for many years [2]. Recently, BPI-ANCA (isotypes IgG and
IgA) have gained focus because of high prevalence in cystic
fibrosis patients [6,14].
In the present study, 71% patients with CF were positive
for anti-BPI-IgG and 33% were positive for anti-BPI-IgA.
Levels of anti-BPI-IgA were expressed as optical density. It
is possible that the high absorbance values are not confined
to the linear part of the curve but possibly on the upper,
flattened part of the curve. These values therefore possibly
should have been even higher.
We have found a highly significant correlation between
BPI-ANCA and pulmonary HRCT findings, scored with a
modified Bhalla score. In this study, we have for the first
time shown that BPI-ANCA are not only closely related to
pulmonary function tests [4,15] and colonization by PSA
[15], but to an established HRCT score that evaluates lung
destruction. HRCT scans confer detailed information of the
distribution and severity of lung damage [8] and scoring of
the pathological findings carry the opportunity to quantify
structural lung damage. Our findings may contribute to a
better understanding of the significance of BPI-ANCA
levels and severity of lung disease in CF.
Thirty-three percent of patients had chronic PSA lung
infection and one additional patient was intermittently PSA
infected. The prevalence of chronic PSA lung infection islow in Norway (35%) [16] compared to Denmark (45%)
[17] or USA (60%) [18]. In accordance with previous
investigations [5,15,19], high levels of BPI-ANCA in our
study group were strongly correlated to chronic PSA lung
infection. It is striking that the Norwegian PSA prevalence is
almost identical with the prevalence of anti-BPI-IgA in our
study group. Prevalence of anti-BPI-IgG was even higher
and all patients with chronic PSA lung infection were
positive for anti-BPI-IgG. Sediva et al. [14] found preva-
lences comparable to ours in their Czech studygroup (77%
anti-BPI-IgG and 29% anti-BPI-IgA), although they do not
comment their PSA prevalence. In Schultz material, the PSA
prevalence was 37%, with prevalence of 48% for anti-BPI-
IgG and 11% for anti-BPI-IgA [20]. Neither Sediva nor
Schultz could demonstrate a significant correlation between
BPI-ANCA and clinical data like pulmonary function tests
or PSA colonization.
The finding of BPI-ANCA in CF infants [14] even before
colonization by PSA may indicate a primary role of BPI-
ANCA in the pathogenesis of CF. Due to the design of the
present study, our youngest patients were six respectively
seven years and both were positive for anti-BPI-IgG without
PSA colonization. However, we did not find a correlation
between age and BPI-ANCA.
All but one patient positive for anti-BPI-IgA had chronic
PSA lung infection. This patient was the oldest of our study
group (40 years old). She showed extensive pulmonary
parenchyma damage (Bhalla score 19) and impaired pul-
monary function (FEV1 40% of predicted). Interestingly,
this patient had normal values for anti-BPI-IgG. Moreover,
she was one of the seven patients with preserved exocrine
pancreatic function.
Regarding pancreatic function, we found a significant
difference between patients with exocrine pancreatic insuf-
ficiency and patients having patent pancreatic function in
terms of anti-BPI-IgG values ( p = 0.009, data not presented
here), reflecting higher anti-BPI-IgG titers in patients with
exocrine pancreatic insufficiency. We have no explanation
for this finding. One could speculate whether this is an
epiphenomenon, which reflects the more common advanced
lung disease in CF patients with pancreatic malfunction.
A substantial and persistent inflammatory response is
elicited by chronic PSA lung infection, although incapable
of clearing the infection. Mechanisms responsible for this
incompetence remain unclear [21]. Increased antibody pro-
duction as response to repetitive bacterial infections is
demonstrated by hypergammaglobulinemia in infected CF
patients and develops gradually during the course of the
disease [22]. In our study group, there was a close correla-
tion between serum levels of total immunoglobulin G and
BPI-ANCA (data not shown). High levels of immunoglobu-
line in many CF patients lead to increased levels of immune
complexes, and finally tissue damage is established via
phagocytosis and the complement pathway [22,23]. The
pathogenetic effect of BPI-ANCA is probably different and
more specific. One may speculate that BPI-ANCA reduce
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thereby contribute to the incompetence in clearing the
infection. BPI and other ANCA antigens origin from poly-
morphonuclear leucocytes (PMN) and are exposed on the
PMN cell surface after release. ANCA binding to such a
membrane bound antigen is thought to activate the PMN
and result in release of proinflammatory cytokines, which
trigger lung inflammation further [24].
In a recent report, Sediva et al. [25] describe that
destruction of PSA, mediated by normal human neutrophiles
was titer-dependent inhibited in the presence of BPI-ANCA.
Still, the role of BPI-ANCA in worsening lung disease, lung
infection and inflammation in CF is complex and not fully
understood.
Our findings may have clinical relevance, as BPI-ANCA
positive patients with CF have poorer clinical outcome,
demonstrated by the close correlations to pulmonary function
and lung parenchyma destruction and thus may prove useful
as a prognostic marker of disease activity. Our findings may
contribute to a better understanding of the significance of
BPI-ANCA levels and severity of lung disease in CF.
Further investigation is needed. Markers of inflammation
e.g. interleukin-1, interleukin-8 and tumour necrosis factor-
a (TNF-a) correlated to BPI-ANCA would be of particular
interest, and we intend to look at these aspects in near
future. Longitudinal studies of BPI-ANCA in infants and
young CF patients and correlating these findings with
pulmonary status could further elucidate the role of these
antibodies in the disease process.Acknowledgements
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